Bioventix PLC provided earnings guidance for the year ended June 30, 2016. The Board announced that revenues for the financial year ended 30 June 2016 are expected to be in excess of £5.3 million. A strong performance during the financial year has been supplemented by a positive exchange rate effect. Since the cost base of the company follows the same trajectory as in previous years, both revenues and profits before tax are expected to be ahead of market expectations for the year ended 30 June 2016.